MedTrace Logo

Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration

NCT01334294 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2014-10-03

No results posted yet for this study

Summary

ForeseeHome, an FDA-approved home device, was specifically designed for unsupervised Preferential-Hyperacuity-Perimeter (PHP) testing of Age Related Macular Degeneration (AMD) patients at home by characterizing central and paracentral metamorphopsia . The purpose of the current study is to evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (OCT).

Conditions

  • Age Related Macular Degeneration
  • Choroidal Neovascularization

Interventions

DEVICE

ForeseeHome

The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.

Sponsors & Collaborators

  • Notal Vision Ltd.

    lead INDUSTRY

Principal Investigators

  • Mark Michels, MD · Retina care specialists

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-12-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01334294 on ClinicalTrials.gov